Medincell SA Cash Flow Conversion Efficiency

Latest as of March 2026: -3.537x

Medincell SA cash flow conversion efficiency. Based on the latest financial reports, Medincell SA (MEDCL) has a cash flow conversion efficiency ratio of -3.537x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-10.84 Million ≈ $-12.67 Million USD) by net assets (€3.06 Million ≈ $3.58 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Medincell SA (2016–2026)

Cash flow conversion efficiency of Medincell SA from 2016 to 2026. This chart illustrates how Medincell SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Medincell SA stock quote for real-time trading data and today's change.

Medincell SA Cash Flow Conversion Ratio Explained

Medincell SA cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Medincell SA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Medincell SA ranked by their cash flow conversion efficiency. Also see MEDCL stock market capitalisation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Vesuvius India Limited NSE:VESUVIUS	0.170x
Kornit Digital Ltd NASDAQ:KRNT	0.009x
Raymond Limited NSE:RAYMOND	-0.011x
Elco Ltd TA:ELCO	0.006x
Tourism Finance Corporation of India Limited NSE:TFCILTD	-0.037x
Apogee Enterprises Inc NASDAQ:APOG	0.015x
Heartland Express Inc NASDAQ:HTLD	0.017x
Asseco Business Solutions S.A. WAR:ABS	0.101x

Annual Cash Flow Conversion Efficiency for Medincell SA (2016–2026)

The table below shows the annual cash flow conversion efficiency of Medincell SA from 2016 to 2026. Review Medincell SA (MEDCL) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2026-03-31	€3.06 Million ≈ $3.58 Million	€-24.55 Million ≈ $-28.71 Million	-8.014x	-573.83%
2025-03-31	€-16.37 Million ≈ $-19.13 Million	€19.46 Million ≈ $22.76 Million	-1.189x	-507.24%
2024-03-31	€-40.82 Million ≈ $-47.73 Million	€-11.92 Million ≈ $-13.94 Million	0.292x	-41.20%
2023-03-31	€-42.29 Million ≈ $-49.45 Million	€-21.00 Million ≈ $-24.56 Million	0.497x	-68.91%
2022-03-31	€-13.37 Million ≈ $-15.63 Million	€-21.36 Million ≈ $-24.97 Million	1.598x	+217.37%
2021-03-31	€8.92 Million ≈ $10.42 Million	€-12.14 Million ≈ $-14.19 Million	-1.361x	-273.23%
2020-03-31	€-15.96 Million ≈ $-18.66 Million	€-12.54 Million ≈ $-14.66 Million	0.786x	+130.79%
2019-03-31	€6.24 Million ≈ $7.30 Million	€-15.93 Million ≈ $-18.63 Million	-2.552x	-652.58%
2018-03-31	€-11.75 Million ≈ $-13.74 Million	€-5.43 Million ≈ $-6.34 Million	0.462x	-68.86%
2017-03-31	€-2.29 Million ≈ $-2.67 Million	€-3.39 Million ≈ $-3.97 Million	1.483x	+2787.40%
2016-03-31	€1.32 Million ≈ $1.55 Million	€68.00K ≈ $79.50K	0.051x	--

About Medincell SA

PA:MEDCL France Biotechnology

Market Cap

$1.11 Billion

€946.58 Million EUR

Market Cap Rank

#9567 Global

#152 in France

Share Price

€26.36

Change (1 day)

+0.38%

52-Week Range

€20.24 - €37.62

All Time High

€38.46